Halozyme Therapeutics, Inc. (HALO)
HALO moved a median of -0.11% 30 minutes after news, and +0.04% by the close. How HALO actually reacts to news — the realized, point-in-time move the market made, measured across 374 labeled events over the last three years with zero look-ahead.
HALO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.02% | 48% | 374 |
| 30-min | -0.11% | 48% | 374 |
| 60-min | -0.12% | 47% | 374 |
| to close | +0.04% | 53% | 371 |
| Middle 50% of HALO reactions | -0.65% to +0.86% |
|---|---|
| Median reaction (30-min) | -0.11% |
| Measured reactions | 374 |
Half of all Halozyme Therapeutics, Inc. news events land between -0.65% and +0.86% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How HALO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 19 | +0.13% | 53% | -1.22% |
| Analyst downgrades | 27 | -0.44% | 33% | -1.35% |
| Rating reiterations | 123 | -0.07% | 46% | +0.07% |
| Price-target raises | 34 | -0.10% | 41% | +0.07% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how HALO ranks against every other measured name →
That’s how HALO usually reacts — get an email when it moves on news →Email me when HALO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to HALO's baseline. Nothing else.
Recent HALO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets | Press release | PR Newswire | +0.85% | -0.74% | |
| Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology | Press release | PR Newswire | +0.85% | -0.74% | |
| Form 8-K HALOZYME THERAPEUTICS, For: Sep 28 | SEC filing · Form 8-K | SEC EDGAR | +0.09% | -2.72% | |
| Halozyme Announces Appointment of Jim Daly to its Board of Directors | Press release | PR Newswire | +0.09% | -2.72% | |
| Form 8-K HALOZYME THERAPEUTICS, For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | +0.42% | -2.66% | |
| Form 8-K HALOZYME THERAPEUTICS, For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | +1.39% | +2.49% | |
| Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 | Press release | PR Newswire | +1.39% | +2.49% | |
| Form 8-K HALOZYME THERAPEUTICS, For: Sep 16 | SEC filing · Form 8-K | SEC EDGAR | +0.80% | +2.43% | |
| Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033 | Press release | PR Newswire | +0.80% | +2.43% | |
| Halozyme to Participate at Upcoming Investor Conferences | Press release | PR Newswire | +2.21% | +3.45% | |
| Form 8-K HALOZYME THERAPEUTICS, For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -0.17% | +1.16% | |
| Halozyme Appoints Dannielle Appelhans to its Board of Directors | Press release | PR Newswire | -0.17% | +1.16% | |
| Form 10-Q HALOZYME THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.33% | +13.32% | |
| Form 8-K HALOZYME THERAPEUTICS, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +2.33% | +13.32% | |
| HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE | Press release | PR Newswire | +2.33% | +13.32% | |
| Halozyme to Report Second Quarter 2026 Financial and Operating Results | Press release | PR Newswire | +0.59% | +4.40% | |
| Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology | Press release | PR Newswire | -0.60% | -1.82% | |
| Form 8-K HALOZYME THERAPEUTICS, For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | -0.83% | +2.03% | |
| Halozyme Appoints David Ramsay as President Drug Delivery | Press release | PR Newswire | -1.26% | -1.86% | |
| Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029 | Press release | PR Newswire | -0.56% | +1.90% | |
| Form 10-Q HALOZYME THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.57% | +0.20% | |
| Form 8-K HALOZYME THERAPEUTICS, For: May 11 | SEC filing · Form 8-K | SEC EDGAR | -1.57% | +0.20% | |
| HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE | Press release | PR Newswire | -1.57% | +0.20% | |
| Form 8-K HALOZYME THERAPEUTICS, For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +0.20% | -2.02% | |
| Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets | Press release | PR Newswire | +0.80% | -1.11% | |
| Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology | Press release | PR Newswire | -0.87% | -0.67% | |
| Form 8-K HALOZYME THERAPEUTICS, For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | +1.09% | +0.71% | |
| Halozyme Appoints Darren Snellgrove as Chief Financial Officer | Press release | PR Newswire | +1.09% | +0.71% | |
| Halozyme to Report First Quarter 2026 Financial and Operating Results | Press release | PR Newswire | -0.72% | +0.76% | |
| Form 8-K HALOZYME THERAPEUTICS, For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | +0.05% | -1.39% | |
| Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology | Press release | PR Newswire | -0.11% | -0.17% | |
| Form ARS HALOZYME THERAPEUTICS, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.10% | -0.56% | |
| Form DEF 14A HALOZYME THERAPEUTICS, For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | -0.10% | -0.56% | |
| Form DEFA14A HALOZYME THERAPEUTICS, | SEC filing · Form DEFA14A | SEC EDGAR | -0.10% | -0.56% | |
| Form 8-K HALOZYME THERAPEUTICS, For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | -0.04% | -2.78% | |
| Halozyme Appoints David Ramsay as Interim Chief Financial Officer | Press release | PR Newswire | -0.04% | -2.78% | |
| U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma | Press release | PR Newswire | +0.00% | +0.88% | |
| Halozyme to Participate in Upcoming Investor Conferences | Press release | PR Newswire | +0.59% | +0.04% | |
| Form 10-K HALOZYME THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.44% | -6.15% | |
| Form 8-K HALOZYME THERAPEUTICS, For: Feb 17 | SEC filing · Form 8-K | SEC EDGAR | -2.44% | -6.15% | |
| HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE | Press release | PR Newswire | -2.44% | -6.15% | |
| Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results | Press release | PR Newswire | -1.32% | -1.24% | |
| Form 8-K HALOZYME THERAPEUTICS, For: Jan 28 | SEC filing · Form 8-K | SEC EDGAR | +1.71% | +2.65% | |
| Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance | Press release | PR Newswire | +1.71% | +2.65% | |
| Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update | Press release | PR Newswire | -0.78% | +1.99% | |
| Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE® | Press release | PR Newswire | -1.20% | -3.61% | |
| Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity | Press release | PR Newswire | -0.37% | +1.35% | |
| U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer | Press release | PR Newswire | -0.86% | -1.32% | |
| Form 8-K HALOZYME THERAPEUTICS, For: Dec 04 | SEC filing · Form 8-K | SEC EDGAR | +0.08% | +0.89% | |
| Form 8-K HALOZYME THERAPEUTICS, For: Dec 04 | SEC filing · Form 8-K | SEC EDGAR | +1.18% | -0.96% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the HALO section they belong to.
Where else HALO is measured.
HALO earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Autolus Therapeutics plc - American Depositary Shares (AUTL) | 377 | -0.00% | 45% |
| Solid Biosciences Inc. (SLDB) | 375 | -0.17% | 46% |
| RITTER PHARMACEUTICALS (RTTR) | 374 | -0.61% | 37% |
| MIRAGEN THERAPEUTICS INC (MGEN) | 369 | -0.39% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Halozyme Therapeutics, Inc.'s median reaction calculated?
Every labeled HALO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 374 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of HALO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does HALO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.